FrancophonIA/ELRC3.0 huggingface dataset:
English: Zykadia contains the active substance ceritinib.
Estonian: Zykadia sisaldab toimeainena tseritiniibi.
English: Results showed that patients given Zykadia lived for an average of 5.4 months without their disease getting worse (progression-free survival) compared with 1.6 months in patients given standard chemotherapy.
Estonian: Tulemuste põhjal oli Zykadiaga ravitud patsientide progresseerumiseta elumus (kui kaua patsiendid elasid haiguse süvenemiseta) keskmiselt 5,4 kuud ning standardse keemiaravi patsientidel 1,6 kuud.
English: What benefits of Zykadia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zykadia kasulikkus?
English: Zykadia has been shown to be effective at treating advanced, ALK-positive NSCLC in three main studies in patients whose disease progressed despite previous treatment with the medicine crizotinib:
Estonian: Zykadia efektiivsust kaugelearenenud ALK-positiivse mitteväikerakk-kopsuvähi ravis tõendati kolmes põhiuuringus, milles osalesid patsiendid, kelle haigus oli hoolimata varasemast ravist krisotiniibiga süvenenud.
English: Patients given Zykadia lived for an average of 16.6 months without their disease getting worse compared with 8.1 months in patients given standard chemotherapy.
Estonian: Progresseerumiseta elumus oli Zykadiat kasutanud patsientidel keskmiselt 16,6 kuud ja standardset keemiaravi saanud patsientidel 8,1 kuud.
English: An overview of Zykadia and why it is authorised in the EU
Estonian: Ülevaade ravimist Zykadia ja ELis müügiloa väljastamise põhjendus
English: It is only used if the NSCLC is ‘ALKpositive', which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
Estonian: Zykadiat kasutatakse üksnes juhul, kui mitteväikerakkkopsuvähk on ALK-positiivne: vähirakkudes on teatud defektid, mis mõjutavad ALK-valku (anaplastilist lümfoomkinaasi) tootvat geeni.
English: The presence of genetic defects affecting ALK (‘ALK-positive' status) has to be confirmed in advance by appropriate methods.
Estonian: Enne ravi alustamist peab olema asjakohaste meetodite abil kinnitatud ALK-positiivsust põhjustavate geenidefektide esinemine.
English: ALK belongs to a family of proteins called receptor tyrosine kinases, which are involved in the growth of cells and the development of new blood vessels that supply them.
Estonian: Need valgud on seotud rakkude kasvamisega ja neid verega varustavate uute veresoonte tekkega.
English: Zykadia has also been shown to be effective at treating patients who had not been treated before in a study in 376 patients.
Estonian: Uuringus, milles osales 376 patsienti, tõendati Zykadia efektiivsust ka varem ravimata patsientide ravis.
English: Why is Zykadia authorised in the EU?
Estonian: ELis Zykadiale väljastatud müügiloa põhjendus
English: Sevohale1 (sevoflurane)
Estonian: Sevohale1 (sevofluraan)
English: The name of the medicine was changed to Sevohale on 29 July 2016.
Estonian: Ravimi nimetus muudeti 29. juulil 2016 Sevohaleks.
English: Further information on Sevohale can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Lisateave Sevohale kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Other information about Sevohale
Estonian: Muu teave Sevohale kohta
English: Together, these combined actions result in loss of consciousness.
Estonian: Nende toimete kombinatsioon kutsub esile teadvusekaotuse.
English: What is Sevohale and what is it used for?
Estonian: Mis on Sevohale ja milleks seda kasutatakse?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Sevohale has been shown to be comparable to SevoFlo.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud ravimi Sevohale võrreldavus ravimiga SevoFlo.
English: Sevocalm received a marketing authorisation valid throughout the EU on 21/06/2016.
Estonian: Sevocalmi müügiluba, mis kehtib kogu Euroopa Liidus, anti 21. juunil 2016.
English: 1 Previously known as Sevocalm
Estonian: 1 Varasem nimetus Sevocalm
English: An overview of Sevohale and why it is authorised in the EU
Estonian: Sevohale ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: Sevohale is given using specialised anaesthetic equipment, usually in a carefully controlled mixture including oxygen.
Estonian: Sevohalet manustatakse spetsiaalse anesteesiaaparatuuriga, tavaliselt koos hoolikalt kontrollitud segus hapnikuga.
English: The dog or cat breathes in this gas mixture, which causes it to become unconscious.
Estonian: Koer või kass hingab gaasisegu sisse ja kaotab selle mõjul teadvuse.
English: No additional studies were needed as Sevohale is a generic medicine that is given by inhalation and contains the same active substance as the reference medicine, SevoFlo.
Estonian: Lisauuringuid ei olnud vaja, sest Sevohale on inhalatsiooniga manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim SevoFlo.
English: When a dog or cat is given a mixture of oxygen and sevoflurane to breathe, the sevoflurane is inhaled into its lungs and is carried by the blood into the brain.
Estonian: Kui koer või kass hingab sisse hapniku ja sevofluraani segu, liigub sevofluraan kopsudesse ning vereringes edasi peaajju.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Sevohale, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Sevohale ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: This means that Sevohale contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called SevoFlo.
Estonian: See tähendab, et Sevohale sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim SevoFlo, millel juba on Euroopa Liidus müügiluba.
English: Therefore, the Agency's view was that, as for SevoFlo, the benefits outweigh the identified risks and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka SevoFlo korral, ületab Sevohale kasulikkus sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: Sevohale is a ‘generic medicine'.
Estonian: Sevohale on geneeriline ravim.
English: Because Sevohale is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Sevohale on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Sevoflurane mimics the action of GABA, a substance that naturally reduces brain activity, and blocks the action of glutamate, which stimulates the action of the brain.
Estonian: Sevofluraan jäljendab GABA (aju talitlust vähendav kehaomane aine) toimet ja blokeerib aju talitlust stimuleeriva aine glutamaadi toime.
English: For more information about using Sevohale, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate Sevohalega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: It contains the active substance sevoflurane, a chemical which is a liquid at room temperature, but when heated becomes a gas (vaporises).
Estonian: Sevohale sisaldab toimeainena sevofluraani, mis on toatemperatuuril vedel, kuid kuumutades gaasiliseks muutuv (aurustuv) keemiline aine.
English: Sevohale is a general anaesthetic for dogs and cats.
Estonian: Sevohale on koertel ja kassidel kasutatav üldanesteetikum.
English: Sevohale is used to bring about and maintain general anaesthesia (loss of consciousness).
Estonian: Seda kasutatakse üldanesteesia (teadvusekaotuse) esilekutsumiseks ja alalhoidmiseks.
English: How is Sevohale used?
Estonian: Kuidas Sevohalet kasutatakse?
English: How does Sevohale work?
Estonian: Kuidas Sevohale toimib?
English: What are the benefits and risks of Sevohale?
Estonian: Milles seisneb Sevohale kasulikkus ja mis riskid ravimiga kaasnevad?
English: How has Sevohale been studied?
Estonian: Kuidas Sevohalet uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Sevohale on retseptiravim.
English: The precautions are the same as for the reference medicine since Sevohale is a generic medicine.
Estonian: Kuna Sevohale on geneeriline ravim, siis on meetmed samad, mis võrdlusravimi korral.
English: Why is Sevohale authorised in the EU?
Estonian: Sevohale Euroopa Liidus heakskiitmise põhjused
English: Date of first authorisation: 15/07/2013 Date of last renewal: 14/06/2018
Estonian: Esmase müügiloa väljastamise kuupäev: 15/07/2013 Müügiloa viimase uuendamise kuupäev: 14/06/2018
English: monograph 0063.
Estonian: monograafias 0063 kirjeldatule.
English: Maternal antibodies may interfere with vaccination.
Estonian: Maternaalsed antikehad võivad mõjutada vaktsineerimist.
English: Revaccination: every six months.
Estonian: Kordusvaktsineerimine: iga 6 kuu järel.
English: Pigs: IM.
Estonian: Siga: IM
English: In trials the following has been demonstrated:
Estonian: Katsed on näidanud järgmist:
English: Schedule should be adjusted accordingly (see section 4.9).
Estonian: Vaktsineerimisgraafikut peab vastavalt sellele kohandama (vt lõik 4.9.
English: These local reactions normally resolve over a period of four weeks post vaccination, but may persist for longer in a small number of animals.
Estonian: Sellised lokaalsed reaktsioonid taanduvad tavaliselt iseeneslikult 4 nädala jooksul pärast vaktsineerimist, kuid vähestel loomadel võivad püsida kauem.
English: BOEHRINGER INGELHEIM ANIMAL HEALTH Netherlands B.V. Houtribweg 39
Estonian: BOEHRINGER INGELHEIM ANIMAL HEALTH Netherlands B.V.
English: According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
Estonian: Vastavalt Euroopa Parlamendi ja nõukogu direktiivi nr 2001/82/EÜ artiklile 71 võib liikmesriik kooskõlas siseriiklike õigusaktidega keelustada immunoloogilise veterinaarravimi tootmise, impordi, omamise, müügi, tarnimise ja/või kasutamise oma territooriumil või osal oma territooriumist, kui on tuvastatud, et:
English: The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of foot-and-mouth disease.
Estonian: Selle veterinaarravimi kasutamine on lubatud ainult teatud tingimustel, mis on kehtestatud Euroopa Ühenduse suu-ja sõrataudi tõrje alaste õigusaktidega.
English: Pigs: 4 weeks after vaccination.
Estonian: Sigadel: 4 nädalat pärast vaktsineerimist.
English: Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest FRANCE
Estonian: Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest Prantsusmaa
English: The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.
Estonian: Aktiivsed toimeained on bioloogilise päritoluga ning mõeldud aktiivse immuunsuse tekitamiseks ning on seetõttu määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad.
English: The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Estonian: Abiained (kaasa arvatud adjuvandid), mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1. on kas lubatud ained, millele Komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele, või määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad, kui neid kasutatakse nii nagu selles veterinaarravimis.
English: * PD50 - 50% protective dose in cattle as described in Ph. Eur.
Estonian: *PD50: 50% veiseid kaitsev doos vastavalt Ph.Eur.
English: Each dose of 2 ml of emulsion contains:
Estonian: Iga 2 ml doosi emulsiooni sisaldab:
English: In cattle, the antibody levels measured were above those shown to be protective.
Estonian: Veistel mõõdetud antikehade tasemed ületasid kaitseks vajaliku.
English: Homogenize the content of the vial by gentle mixing before the insertion of needle.
Estonian: Viaali sisu tuleb enne nõela sisestamist õrnalt segades homogeniseerida.
English: 10 doses 25 doses
Estonian: 10 doosi 25 doosi
English: No antibodies to NSP were detected using the PrioCHECK FMDV NS test kit:
Estonian: PrioCHECK FMDV NS testi kasutamisel ei leitud NSP vastaseid antikehi:
English: Cattle and sheep: 7 days after vaccination.
Estonian: Veistel ja lammastel: 7 päeva pärast vaktsineerimist.
English: Liquid paraffin 537 mg. White emulsion after shaking.
Estonian: Vedel parafiin 537 mg Peale raputamist valge emulsioon.
English: Schedule should be adjusted accordingly (see section “dosage”).
Estonian: Vaktsineerimisgraafikut peab vastavalt sellele kohandama (vt punkt “Annustamine“).
English: Do not mix the vaccine by vigorous shaking because it leads to entrapment of air bubbles.
Estonian: Vaktsiini ei tohi segada tugevalt raputades, sest see põhjustab õhumullide tekke.
English: A slight increase of rectal temperature of up to 1.2 °C for 4 days post-vaccination with no other generalised clinical signs is commonly observed.
Estonian: Sageli täheldati rektaalse temperatuuri kerget tõusu kuni 1,2 °C 4 vaktsineerimisjärgse päeva jooksul ilma muude üldnähtudeta.
English: Mannide mono-oleate Polysorbate 80
Estonian: Vedel parafiin Manniidmonooleaat Polüsorbaat 80
English: The number and type of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label.
Estonian: Lõpp-tootes esinevate tüvede arv ja tüüp kohaldatakse vastavalt kehtivale epidemioloogilisele olukorrale lõpp-toote valmimise ajal ning see on ära toodud etiketil.
English: Maximum three of the following purified, inactivated foot-and-mouth disease virus strains:
Estonian: Maksimaalselt kolm järgnevat puhastatud, inaktiveeritud suu- ja sõrataudi viirustüve:
English: Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Estonian: Inaktiveeritud suu- ja sõrataudi antigeenid on puhastatud ning ei sisalda piisavas koguses mittestruktuurseid valke (NSP), tekitamaks antikehade vastust pärast kolmevalentse vaktsiini manustamist, mis sisaldab antigeene koguses vähemalt 15 PD50 tüve kohta 1 doosis (2 ml).
English: Vaccination of cattle with strains O1 Manisa, O1 BFS, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia1 Shamir and SAT2 Saudi Arabia resulted in a reduction of clinical signs in animals exposed to infection.
Estonian: Veiste vaktsineerimisel tüvedega O1 Manisa, O1 BFS, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia1 Shamir ja SAT2 Saudi Arabia oli tulemuseks kliiniliste tunnuste vähenemine viirustega kokku puutunud loomadel.
English: Cattle and sheep: for subcutaneous use.
Estonian: Veis ja lammas: subkutaanselt kasutamiseks.
English: Cattle and sheep: SC.
Estonian: Veis ja lammas: SC
English: Avoid accidental contamination of the vaccine after first broaching and during use.
Estonian: Rakendada tavalisi aseptikameetmeid: hoiduda vaktsiini saastamisest pärast viaali esmast läbistamist ning kasutamise ajal.
English: 10 doses 25 doses 50 doses 100 doses 150 doses 10 x 10 doses 10 x 25 doses 10 x 50 doses 10 x 100 doses 10 x 150 doses
Estonian: 10 doosi 25 doosi 50 doosi 100 doosi 150 doosi 10 x 10 doosi 10 x 25 doosi 10 x 50 doosi 10 x 100 doosi 10 x 150 doosi
English: The NETHERLANDS
Estonian: Holland
English: Active substances:
Estonian: Aktiivne toimeaine:
English: The import, possession, sale, supply and/or use of this veterinary medicinal product may be prohibited in a Member State on the whole or part of its territory, see package leaflet for further information.
Estonian: Selle veterinaarravimi import, omamine, müük, tarnimine ja /või kasutamine võib olla liikmesriigis selle tervel territooriumil keelatud - täpsema teabe saamiseks lugege pakendi infolehte.
English: EXP {month/year} Once broached use immediately.
Estonian: EXP {kuu/aasta} Pärast esmast avamist kasutada koheselt.
English: White emulsion after shaking.
Estonian: Peale raputamist valge emulsioon.
English: Sodium chloride Potassium dihydrogen phosphate Potassium chloride Disodium phosphate anhydrous Potassium hydroxide Water for injections.
Estonian: Trometamool Naatriumkloriid Kaaliumdivesinikfosfaat Kaaliumkloriid Veevaba dinaatriumfosfaat Kaaliumhüdroksiid Süstevesi
English: Duration of immunity: vaccination of cattle, sheep and pigs induced the production of neutralising antibodies that persisted for at least 6 months.
Estonian: Immuunsuse kestus: veiste, lammaste ja sigade vaktsineerimine kutsub esile neutraliseerivate antikehade tekke, mis püsivad vähemalt 6 kuud.
English: 50 doses 100 doses 150 doses
Estonian: 50 doosi 100 doosi 150 doosi
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Bottle of 10 or 25 doses
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL Pudel 10 ja 25 doosi
English: - in cattle following administration of a double dose followed by a single dose 7 weeks later and a third vaccination with a single dose 13 weeks after the second dose, - in sheep following administration of a double dose followed by a single dose 5 weeks later and a third vaccination with a single dose 7 weeks after the second dose, - in pigs following administration of a double dose followed by a single dose 3 weeks later and a third vaccination with a single dose 7 weeks after the second dose.
Estonian: - veistel pärast kahekordse doosi manustamist, millele järgnes 7 nädalat hiljem vaktsineerimine 1 doosiga ning 13 nädalat pärast teist vaktsineerimist kolmas vaktsineerimine 1 doosiga - lammastel pärast kahekordse doosi manustamist, millele järgnes 5 nädalat hiljem vaktsineerimine 1 doosiga ning 7 nädalat pärast teist vaktsineerimist kolmas vaktsineerimine 1 doosiga - sigadel pärast kahekordse doosi manustamist, millele järgnes 3 nädalat hiljem vaktsineerimine 1 doosiga ning 7 nädalat pärast teist vaktsineerimist kolmas vaktsineerimine 1 doosiga.
English: one dose of 2 ml, by subcutaneous route.
Estonian: 1 doos 2 ml, subkutaanselt
English: Do not warm the product before use.
Estonian: Enne kasutamist vaktsiini mitte soojendada.
English: Pigs: for intramuscular use.
Estonian: Siga: intramuskulaarselt manustamiseks.
English: Shelf life of the veterinary medicinal product not containing strain Asia1 Shamir as packaged for sale: 6 months.
Estonian: Müügipakendis veterinaarravimi, mis ei sisalda tüve Asia1 Shamir, kõlblikkusaeg: 6 kuud.
English: Cattle, sheep: SC. Pigs: IM.
Estonian: Veis, lammas: SC Siga: IM
English: Vaccination of pigs with strains O Taiwan 3/97 and A22 Iraq resulted in a reduction of clinical signs in animals exposed to infection.
Estonian: Sigade vaktsineerimisel tüvedega O Taiwan 3/97 ja A22 Iraq oli tulemuseks kliiniliste tunnuste vähenemine viirusega kokku puutunud loomadel.
English: In some cases ulceration may occur at the injection site.
Estonian: Mõnedel juhtudel võib süstekohas tekkida haavand.
English: The safety of the veterinary medicinal product has not been established during lactation.
Estonian: Preparaadi ohutus kasutamisel laktatsiooniperioodil ei ole kindlaks tehtud.
English: When animals have to be vaccinated in presence of maternal antibodies, revaccination at 8-10 weeks is recommended.
Estonian: Kui loomi peab vaktsineerima ajal kui neil esinevad maternaalsed antikehad, on soovituslik teostada kordusvaktsineerimine 8-10 nädala vanuses.
English: Primary vaccination: Cattle from 2 weeks of age:
Estonian: Esmane vaktsineerimine: Veis alates 2 nädala vanusest:
English: When very young pigs (at 2 weeks old) have to be vaccinated, revaccination at 8-10 weeks is recommended.
Estonian: Vaktsineerides väga noori põrsaid (2 nädala vanuses), on soovituslik teostada kordusvaktsineerimine 8-10 nädala vanuses.
English: If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.
Estonian: Kui olete juhuslikult endale seda veterinaarravimit süstinud, võtta kaasa pakendi infoleht ja pöörduda viivitamatult arsti poole, isegi kui süstitud kogus oli väga väike.
English: Shelf life of the veterinary medicinal product containing strain Asia1 Shamir as packaged for sale: 2 months.
Estonian: Müügipakendis veterinaarravimi, mis sisaldab tüve Asia1 Shamir, kõlblikkusaeg: 2 kuud.
English: FMD antigen ≥ 6 PD50 per strain
Estonian: FMD antigeen ≥ 6 PD50 tüve kohta
English: Following repeated administration at short intervals, the intensity of these reactions may be increased.
Estonian: Korduvate lühikeste intervallidega manustamisel võivad kõrvaltoimed tugevneda.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT
Estonian: TOIMEAINE(TE) JA ABIAINETE SISALDUS
English: Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.
Estonian: Veiste, lammaste ja sigade aktiivne immuniseerimine alates 2 nädala vanusest suu ja -sõrataudi vastu, et vähendada kliinilisi tunnuseid.
English: This is best achieved by inverting the vial several times base over apex.
Estonian: Parim viis selleks on pöörates viaali korduvalt põhi ülespoole ja tagasi.
English: To stimulate active immunity of cattle, sheep and pigs against purified, inactivated foot-and-mouth disease virus strain antigens related to those contained in the vaccine.
Estonian: Aktiivse immuunsuse stimuleerimiseks veistel, lammastel ja sigadel puhastatud, inaktiveeritud suu- ja sõrataudi viirustüvede antigeenide vastu, mis sisalduvad vaktsiinis.
English: Purified, inactivated foot-and-mouth disease virus strain antigens, at least 6 PD50* per strain.
Estonian: Puhastatud, inaktiveeritud suu- ja sõrataudi viirustüvede antigeene vähemalt 6 PD50* tüve kohta.
English: Vaccination of pigs with strain Asia1 Shamir resulted in a reduction of clinical signs and virus shedding in animals exposed to infection.
Estonian: Sigade vaktsineerimisel tüvega Asia1 Shamir oli tulemuseks kliiniliste tunnuste vähenemine ja viiruse leviku vähenemine viirusega kokku puutunud loomadel.
English: Vaccination of sheep with strain O1 Manisa resulted in a reduction of clinical signs in animals exposed to infection.
Estonian: Lammaste vaktsineerimisel tüvega O1 Manisa oli tulemuseks kliiniliste tunnuste vähenemine viirusega kokku puutunud loomadel.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated ) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10000-st ravitud loomast, kaasaarvatud üksikjuhud).